Data Sheet 1_Elevated relative humidity significantly decreases cannabinoid concentrations while delaying flowering development in Cannabis sativa L..docx by Ingrid Carolina Corredor-Perilla (22631510)

“…Furthermore, high RH significantly suppressed cannabinoid accumulation: cannabidiolic acid (CBD-A), cannabidiol (CBD), and cannabichromenic acid (CBC-A) levels decreased by approximately 4.9-fold, 3.2-fold, and 13-fold, respectively. …”

Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

“…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …”

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2018 ^a indicates ≥1.50 SD (17.9) from the mean (32.9... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (11.1-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2015 ^a indicates ≥1.50 SD (20.2) from the mean (36.... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2017 ^a indicates ≥1.50 SD (18.0) from the mean (33.1... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (8.5-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2019 ^a indicates ≥1.50 SD (16.8) from the mean (31.0... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (8.6-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2020 ^a indicates ≥1.50 SD (16.0) from the mean (29.9... by Luke R. Cavanah (19022435)

Subjects:

Large state-wide variation (10.2-fold) in number of clozapine prescriptions per thousand Medicare Part D enrollees in 2016 ^a indicates ≥1.50 SD (19.2) from the mean (34.... by Luke R. Cavanah (19022435)

Subjects:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

National (A) Medicare prescription rates per thousand Part D enrollees and (B) Medicare spending for clozapine gradually decreased for 2015-2020. by Luke R. Cavanah (19022435)

Subjects:

HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles. by Perumal Vivekanandhan (4863484)

Minimal dataset. by Jennifer M. Kwan (3350321)

Subjects:

Kaplan-Meier curves and time-dependent Cox regression for outcome of mortality. by Jennifer M. Kwan (3350321)

Subjects:

Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

Subjects:

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Log2 fold change (FC) of the overlaps of lipid metabolites between the study groups and those significant metabolites that appear exclusively in a single group (unique) represented... by Laia Bertran (3685147)